Geron | GERN - Gross Profit On Sales


Geron reported $50.14M in Gross Profit on Sales for its fiscal quarter ending in March of 2026.





Gross Profit On Sales Change Date
Amgen USD 6.89B 415M Dec/2025
Bio Techne USD 208.29M 17.01M Mar/2026
Cassava Sciences USD -3.96M 1.16M Sep/2025
Cytokinetics USD 19.2M 1.44M Mar/2026
Esperion Therapeutics USD 140.59M 94.57M Dec/2025
Exelixis USD 590.86M 18.68M Mar/2026
Genmab DKK 977M 13M Dec/2025
Geron USD 50.14M 3.44M Mar/2026
Gilead Sciences USD 5.52B 791M Mar/2026
Incyte USD 1.17B 217.51M Mar/2026
MacroGenics USD 31.11M 30.14M Dec/2025
Novartis USD 10.07B 184M Mar/2026
Novavax USD 125.04M 76.09M Dec/2025